{
    "clinical_study": {
        "@rank": "29991", 
        "arm_group": {
            "arm_group_label": "Metformin + canagliflozin (JNJ-28431754)", 
            "arm_group_type": "Experimental", 
            "description": "Each volunteer will receive a single dose of metformin on Day 1 followed by canagliflozin (JNJ-28431754) once daily on Days 4 to 7. On Day 8, volunteers will receive a single dose of canagliflozin in combination with a single dose of metformin."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate whether there is a drug-drug interaction between\n      multiple doses of canagliflozin (JNJ-28431754) and a single dose of metformin. The safety\n      and tolerability of canagliflozin will also be assessed."
        }, 
        "brief_title": "A Study to Investigate Whether Pharmacokinetic and Pharmacodynamic Interactions Exist Between Metformin and Canagliflozin (JNJ-28431754) in Healthy Volunteers", 
        "completion_date": {
            "#text": "November 2007", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "This study is an open-label (all volunteers and study staff know the identity of the\n      assigned treatment), fixed sequence (all volunteers receive the same medication on the same\n      days), single and multiple-dose study to determine how metformin (a blood glucose-lowering\n      agent used to treat patients with diabetes) affects the pharmacokinetics (ie, how the body\n      affects the drug) and the pharmacodynamics (ie, how the drug affects the body) of\n      canagliflozin (a drug currently being investigated for the treatment of type 2 diabetes\n      mellitus). The effect of canagliflozin on the pharmacokinetics and pharmacodynamics of\n      metformin will also be evaluated. The study will consist of 3 phases: a screening phase, an\n      open-label treatment phase, and an end-of-study (or follow-up) phase. Each volunteer will\n      participate in the study for approximately 39 days."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Volunteers must have a Body Mass Index (BMI [weight (kg) / height (m)2]) between 18.5\n             and 35 kg/m2, inclusive\n\n          -  Volunteers must be non-smokers or non-tobacco users\n\n        Exclusion Criteria:\n\n        - History of or currently active illness that the Investigator considers to be clinically\n        significant and should exclude the volunteer from the study or that could interfere with\n        the interpretation of the study results"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 20, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01756417", 
            "org_study_id": "CR013636", 
            "secondary_id": "28431754NAP1004"
        }, 
        "intervention": [
            {
                "arm_group_label": "Metformin + canagliflozin (JNJ-28431754)", 
                "description": "One 1,000 mg tablet of metformin taken orally (by mouth) on Day 1 and Day 8.", 
                "intervention_name": "Metformin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Metformin + canagliflozin (JNJ-28431754)", 
                "description": "Four 25 mg tablets of canagliflozin (JNJ-28431754) taken orally on Days 4 through 8.", 
                "intervention_name": "Canagliflozin (JNJ-28431754)", 
                "intervention_type": "Drug", 
                "other_name": "JNJ-28431754"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Metformin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Healthy", 
            "Canagliflozin (JNJ-28431754)", 
            "Metformin", 
            "Pharmacokinetics", 
            "Pharmacodynamics"
        ], 
        "lastchanged_date": "February 26, 2013", 
        "number_of_arms": "1", 
        "official_title": "An Open-Label, Fixed Sequence, Single and Multiple Dose Study in Male and Female Subjects to Investigate the Potential for Pharmacokinetic and Pharmacodynamic Interaction Between Metformin and JNJ-28431754", 
        "overall_official": {
            "affiliation": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.", 
            "last_name": "Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2007", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Cmax (a measure of the body's exposure to canagliflozin [JNJ-28431754]) will be compared before and after administration of a single dose of metformin.", 
                "measure": "The maximum plasma concentration (Cmax) of canagliflozin (JNJ-28431754)", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 8"
            }, 
            {
                "description": "AUC (a measure of the body's exposure to canagliflozin [JNJ-28431754]) will be compared before and after administration of a single dose of metformin.", 
                "measure": "The area under the plasma concentration-time curve (AUC) for canagliflozin (JNJ-28431754)", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 8"
            }, 
            {
                "description": "Cmax (a measure of the body's exposure to metformin will be compared before and after administration of multiple doses of canagliflozin (JNJ-28431754).", 
                "measure": "The maximum plasma concentration (Cmax) of metformin", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 8"
            }, 
            {
                "description": "AUC (a measure of the body's exposure to metformin will be compared before and after administration of multiple doses of canagliflozin (JNJ-28431754).", 
                "measure": "The area under the plasma concentration-time curve (AUC) for metformin", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 8"
            }, 
            {
                "description": "24-hour urine glucose excretion will be compared following a single dose of metformin, multiple doses of canagliflozin (JNJ-28431754), or multiple doses of canagliflozin in combination with a single dose of metformin.", 
                "measure": "24-hour urine glucose excretion", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 10"
            }, 
            {
                "description": "24-hour area under the serum glucose concentration-time curve will be compared following a single dose of metformin, multiple doses of canagliflozin (JNJ-28431754), or multiple doses of canagliflozin in combination with a single dose of metformin.", 
                "measure": "24-hour area under the serum glucose concentration-time curve", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 8"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01756417"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "The number of volunteers with adverse events as a measure of safety and tolerability", 
            "safety_issue": "No", 
            "time_frame": "up to 18 days"
        }, 
        "source": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2007", 
        "study_design": "Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}